PT2281576E - Micela polimérica do tipo de direcionamento ativo com fármaco no seu interior e composição medicinal - Google Patents
Micela polimérica do tipo de direcionamento ativo com fármaco no seu interior e composição medicinalInfo
- Publication number
- PT2281576E PT2281576E PT98030687T PT09803068T PT2281576E PT 2281576 E PT2281576 E PT 2281576E PT 98030687 T PT98030687 T PT 98030687T PT 09803068 T PT09803068 T PT 09803068T PT 2281576 E PT2281576 E PT 2281576E
- Authority
- PT
- Portugal
- Prior art keywords
- drug
- micelle
- target
- cell
- radial arrangement
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Organic Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008194825 | 2008-07-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2281576E true PT2281576E (pt) | 2013-10-01 |
Family
ID=41610525
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT98030687T PT2281576E (pt) | 2008-07-29 | 2009-07-29 | Micela polimérica do tipo de direcionamento ativo com fármaco no seu interior e composição medicinal |
Country Status (13)
Country | Link |
---|---|
US (1) | US8741339B2 (pt) |
EP (1) | EP2281576B1 (pt) |
JP (1) | JP4538666B2 (pt) |
KR (2) | KR101468268B1 (pt) |
CN (1) | CN101808668B (pt) |
AU (1) | AU2009277456B2 (pt) |
CA (1) | CA2695611C (pt) |
DK (1) | DK2281576T3 (pt) |
ES (1) | ES2432152T3 (pt) |
HK (1) | HK1148216A1 (pt) |
PL (1) | PL2281576T3 (pt) |
PT (1) | PT2281576E (pt) |
WO (1) | WO2010013836A1 (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8524783B2 (en) | 2009-04-30 | 2013-09-03 | Intezyne Technologies, Incorporated | Polymer micelles containing anthracylines for the treatment of cancer |
US8524784B2 (en) | 2009-04-30 | 2013-09-03 | Intezyne Technologies, Incorporated | Polymer micelles containing anthracylines for the treatment of cancer |
JP5086497B1 (ja) * | 2011-03-31 | 2012-11-28 | ナノキャリア株式会社 | ボロン酸化合物を含有したブロック共重合体を含む医薬組成物 |
US9701740B2 (en) | 2011-04-01 | 2017-07-11 | Yale University | Cell-penetrating anti-DNA antibodies and uses thereof inhibit DNA repair |
CN104093768B (zh) | 2011-11-17 | 2016-09-21 | 国立大学法人东京大学 | 导入有苯基硼酸基的嵌段共聚物及其使用 |
EP2842546A4 (en) | 2012-04-27 | 2015-12-30 | Univ Tokyo | UNITARY STRUCTURE-TYPE PHARMACEUTICAL COMPOSITION FOR NUCLEIC ACID ADMINISTRATION |
KR20160007529A (ko) | 2013-05-17 | 2016-01-20 | 나노캬리아 가부시키가이샤 | 중합체 미셀 의약 조성물 |
EP3141243B1 (en) | 2014-05-08 | 2020-07-08 | The University of Tokyo | Pharmaceutical composition |
US20180092859A1 (en) * | 2015-04-02 | 2018-04-05 | The Research Foundation For The State University Of New York | A Supramolecular Chitosan Complex Drug Delivery Platform |
JP2019518040A (ja) | 2016-06-15 | 2019-06-27 | イェール ユニバーシティーYale University | 腫瘍に対して標的化されるナノキャリアの抗体媒介性自触反応的送達 |
US20190330317A1 (en) | 2016-06-15 | 2019-10-31 | Yale University | Anti-guanosine antibody as a molecular delivery vehicle |
JPWO2018025699A1 (ja) * | 2016-08-02 | 2019-05-30 | 日本化薬株式会社 | アクティブターゲティング型高分子誘導体、その高分子誘導体を含む組成物、及びそれらの用途 |
JP6644326B2 (ja) | 2017-08-31 | 2020-02-12 | 国立大学法人 東京大学 | 核酸搭載ユニット型ポリイオンコンプレックス |
WO2021145586A1 (ko) * | 2020-01-15 | 2021-07-22 | 주식회사 슈퍼노바 바이오 | 국소 지방 감소용 기체 발포형 마이셀 |
WO2023056450A1 (en) | 2021-09-30 | 2023-04-06 | Yale University | Compositions and methods for the treatment of autosomal dominant polycystic kidney disease and other diseases having upregulated mtor activity |
WO2023176809A1 (ja) * | 2022-03-17 | 2023-09-21 | 日油株式会社 | ポリエチレングリコール誘導体の製造方法 |
WO2024050524A1 (en) | 2022-09-01 | 2024-03-07 | University Of Georgia Research Foundation, Inc. | Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1389090A2 (en) * | 2001-04-26 | 2004-02-18 | Board of Regents, The University of Texas System | Diagnostic imaging compositions, their methods of synthesis and use |
WO2002087497A2 (en) | 2001-04-26 | 2002-11-07 | Board Of Regents, The University Of Texas System | Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use |
US7371781B2 (en) * | 2003-09-22 | 2008-05-13 | University Of Utah Research Foundation | Tumor environment-induced ligand-expressing nanocarrier system |
US8697031B2 (en) * | 2004-06-04 | 2014-04-15 | Case Western Reserve University | Dual function polymer micelles |
US7638558B2 (en) * | 2005-04-01 | 2009-12-29 | Intezyne Technologies, Inc. | Polymeric micelles for drug delivery |
JP4992090B2 (ja) * | 2005-05-02 | 2012-08-08 | 国立大学法人 東京大学 | 静電結合型高分子ベシクル |
JP2009512696A (ja) * | 2005-10-20 | 2009-03-26 | セントカー・インコーポレーテツド | 標的化イムノリポソームの調製法 |
JP5028564B2 (ja) * | 2005-10-31 | 2012-09-19 | 宮崎県 | 肝疾患治療用又は予防用の血中滞留型多相エマルション製剤及びその製造方法 |
WO2007066781A1 (ja) * | 2005-12-05 | 2007-06-14 | Nanocarrier Co., Ltd. | フッ素系有機溶媒を用いた薬物封入ポリマーミセルを含有する医薬組成物の製造方法 |
CA2650422A1 (en) * | 2006-04-24 | 2007-11-08 | Nanocarrier Co., Ltd. | Process for producing polymer micelles encapsulating low molecular weight drugs |
DE602007014087D1 (de) * | 2006-10-19 | 2011-06-01 | Nanocarrier Co Ltd | Blockcopolymer für wirkstoffkonjugate und deren pharmazeutische zusammensetzungen |
WO2008106129A2 (en) * | 2007-02-26 | 2008-09-04 | Wisconsin Alumni Research Foundation | Polymeric micelles for combination drug delivery |
-
2009
- 2009-07-29 AU AU2009277456A patent/AU2009277456B2/en not_active Ceased
- 2009-07-29 JP JP2009551910A patent/JP4538666B2/ja not_active Expired - Fee Related
- 2009-07-29 DK DK09803068.7T patent/DK2281576T3/da active
- 2009-07-29 ES ES09803068T patent/ES2432152T3/es active Active
- 2009-07-29 CA CA2695611A patent/CA2695611C/en not_active Expired - Fee Related
- 2009-07-29 PT PT98030687T patent/PT2281576E/pt unknown
- 2009-07-29 KR KR1020117014312A patent/KR101468268B1/ko active IP Right Grant
- 2009-07-29 CN CN2009801004628A patent/CN101808668B/zh not_active Expired - Fee Related
- 2009-07-29 KR KR1020107006136A patent/KR20100055498A/ko active Application Filing
- 2009-07-29 EP EP09803068.7A patent/EP2281576B1/en not_active Not-in-force
- 2009-07-29 US US12/672,496 patent/US8741339B2/en active Active
- 2009-07-29 PL PL09803068T patent/PL2281576T3/pl unknown
- 2009-07-29 WO PCT/JP2009/063838 patent/WO2010013836A1/ja active Application Filing
-
2011
- 2011-03-10 HK HK11102396.3A patent/HK1148216A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CN101808668A (zh) | 2010-08-18 |
JP4538666B2 (ja) | 2010-09-08 |
EP2281576B1 (en) | 2013-07-24 |
CA2695611A1 (en) | 2010-01-29 |
US8741339B2 (en) | 2014-06-03 |
WO2010013836A1 (ja) | 2010-02-04 |
AU2009277456B2 (en) | 2011-05-26 |
ES2432152T3 (es) | 2013-12-02 |
JPWO2010013836A1 (ja) | 2012-01-12 |
HK1148216A1 (en) | 2011-09-02 |
EP2281576A4 (en) | 2011-07-20 |
DK2281576T3 (da) | 2013-10-28 |
CN101808668B (zh) | 2012-06-27 |
US20100221320A1 (en) | 2010-09-02 |
KR20100055498A (ko) | 2010-05-26 |
EP2281576A1 (en) | 2011-02-09 |
KR20110075054A (ko) | 2011-07-05 |
CA2695611C (en) | 2011-02-01 |
PL2281576T3 (pl) | 2013-12-31 |
KR101468268B1 (ko) | 2014-12-02 |
AU2009277456A1 (en) | 2010-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1148216A1 (en) | Active targeting type polymeric micelle carrying drug enclosed therein and medicinal composition | |
MX2010004788A (es) | Sistema de liberacion transdermica. | |
WO2008002434A3 (en) | Medical devices for release of low solubility therapeutic agents | |
WO2010005723A3 (en) | Drug loaded polymeric nanoparticles and methods of making and using same | |
WO2007084460A3 (en) | Pharmaceutical compositions with enhanced stability | |
WO2008094834A3 (en) | Multi-functional drug carriers | |
JO2932B1 (en) | Lyspro insulin compounds linked to PEG | |
MX347056B (es) | Composiciones farmaceuticas. | |
EP3492069A3 (en) | Pharmaceutical compositions | |
WO2008141110A3 (en) | Polyglutamate conjugates and polyglutamate-amino acid conjugates having a plurality of drugs | |
WO2009105432A3 (en) | Devices and methods for delivery of a therapeutic agent through a pneumostoma | |
WO2005099667A3 (en) | Drug delivery compositions | |
WO2011112229A3 (en) | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device | |
WO2006044421A3 (en) | Cardiac safe, rapid medication delivery | |
WO2008005176A3 (en) | Electroactive polymer radiopaque marker | |
MX354603B (es) | Formulaciones de transferencia sostenida de compuestos de risperidona. | |
WO2008054466A3 (en) | Delivery of biologically active materials using core-shell tecto (dendritic polymers) | |
WO2010125475A3 (en) | Sustained release formulations comprising gnrh analogues | |
MA34832B1 (fr) | Compositions biodegradables d'administration de medicaments | |
WO2009100181A3 (en) | Absorbent ingestible agents and associated methods of manufacture and use | |
WO2011116139A3 (en) | Improved pharmaceutical compositions comprising cck- 8 and methods of delivery | |
WO2010138544A3 (en) | Oral care formulations that enhance amount of soluble zinc | |
MX2013014461A (es) | Formulaciones de liberacion sostenida para el suministro de proteinas al ojo y metodos para prepararlas. | |
WO2007131193A3 (en) | Main chain acid-degradable polymers for the delivery of bioactive materials | |
MY157187A (en) | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance |